Issue 367: April 1, 2011
 Scott Minick, President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology.
|
Issue 366: March 25, 2011
 Robert Shore, M.D., CEO, and Timothy Sullivan, Executive Vice President,
Cornerstone Pharmaceuticals, on the company’s drug delivery technology targeting cancer cell metabolism.
|
Issue 364: March 11, 2011
 Robert L. Kirkman, M.D., President and CEO, and Scott Peterson, Ph.D., Vice President of Research and Development, Oncothyreon, on the company’s PI3K inhibitor.
|
Issue 363: March 4, 2011
 Ernest Wong, Ph.D., M.B.A., Vice President, YM Biosciences, about the company’s JAK inhibitor program in myelofibrosis.
|
Issue 362: February 25, 2011
 Masayuki Yazawa, Ph.D., Postdoctoral Research Fellow, Stanford University, on the use of iPS cells to treat Timothy Syndrome.
|
Issue 361: February 18, 2011
 William S. Marshall, Ph.D. President and CEO of miRagen Therapeutics, about the company’s miRNA-targeted drugs.
|
Issue 358: January 28, 2011
 Arthur Sands, M.D., Ph.D., President and CEO, Lexicon Pharmaceuticals, about the company’s development programs and partnering strategy.
|
Issue 356: January 14, 2011
 Katrine Bosley, CEO of Avila Therapeutics, about the company’s discovery platform for targeted covalent drugs.
|
Issue 354: December 23, 2010
 Robert Kneller, J.D., M.D., M.P.H., Professor, Research Center for Advanced Science and Technology (RCAST), University of Tokyo, on the differences between pharma and academia in drug discovery innovation.
|
Issue 353: December 17, 2010
 Aris Persidis, PhD., President and Co-Founder, Biovista Inc., on using mechanism of action to predict safety and efficacy.
|
Issue 351: December 3, 2010
 Thomas Hughes, Ph.D., President and CEO of Zafgen Inc., on the company’s lead candidate compound that promotes sustained weight loss through MetAP2 inhibition
|
Issue 350: November 19, 2010
   Eggehard Holler, Ph.D., University of Regensburg, Julia Ljubimova, M.D., Ph.D., Cedars-Sinai Medical Center, and Maurizio Vecchione, CEO, Arrogene Nanotechnology, on a nanoconjugate technology for treating brain …
|
Issue 348: November 5, 2010
 John E. Wennberg, M.D., M.P.H., Peggy Y. Thomson Professor in the Evaluative Clinical Sciences, Dartmouth Medical School, on a rational approach to supply and demand in medicine.
|
Issue 346: October 22, 2010
 Tillman U. Gerngross, Ph.D., CEO of Adimab Inc., on the company’s novel antibody discovery platform.
|
Issue 343: October 1, 2010
 Kobi M. Sethna, President and CEO, Nereus Pharmaceuticals, on leveraging marine microbes as a source of novel pharmaceutical agents.
|
Issue 342: September 24, 2010
 Richard L. Atkinson, M.D., Clinical Professor of Pathology, Virginia Commonwealth University, and President, Obetech, LLC, on the evidence for a causal link between AD36 and obesity.
|
Issue 341: September 17, 2010
 Kathleen Sereda Glaub, President, Plexxikon, on the company’s lead drug candidate for melanoma.
|
Issue 337: August 20, 2010
 Harald Fricke, M.D., Ph.D., CMO and COO, Apogenix, on an innovative therapeutic approach to treating glioblastoma.
|
Issue 336: August 6, 2010
 Stephen Engle, Chairman and CEO, XOMA, on developing a therapeutic antibody-based approach to diabetes treatment.
|
Issue 334: July 23, 2010
 Soichi Matsuno, Advisor, Eisai Co., Ltd., on how the company’s pioneering spirit has contributed to its global expansion.
|
Issue 333: July 15, 2010
 Maria L. Maccecchini, Ph.D., President & CEO, QR Pharma, on an approach to inhibiting amyloid formation in targeting mild cognitive impairment and Alzheimer’s disease.
|
Issue 332: July 7, 2010
 Marc Cantillon, M.D., Director of the Coalition Against Major Diseases at the Critical Path Institute, on accelerating Alzheimer’s drug development through data collaboration.
|
Issue 328: June 4, 2010
 Gordon McCauley, President and CEO, Allon Therapeutics Inc., on targeting neurodegenerative diseases with activity-dependent neuroprotective protein.
|
Issue 326: May 21, 2010
  Robert Gould, Ph.D., President and CEO, and Jason Rhodes, EVP and Chief Business Officer of Epizyme, on transforming cancer therapy via HMT inhibition.
|
Issue 325: May 14, 2010
 Tom Smart, Chairman and CEO, AnaptysBio, on leveraging a novel platform for antibody generation.
|
Issue 322: April 23, 2010
 Roger H. Unger, M.D., Professor of Internal Medicine, University of Texas South Western Medical Center, on the comparison of leptin and insulin levels in mouse models of type 1 diabetes.
|
Issue 321: April 16, 2010
 Adam Bosworth, Founder and CTO of Keas, on using intelligent computing to improve patient outcomes.
|
Issue 316: March 12, 2010
 Christopher S. Meldrum, President, Pique Therapeutics, on non-immunogenic cancer treatment using allogenic vaccine therapies.
|
Issue 314: February 26, 2010
 Andrew M. Thompson, Co-Founder and CEO, Proteus Biomedical, on the company’s advancements in intelligent medicine.
|
Issue 312: February 12, 2010
 Stephen H. Friend, M.D., Ph.D., President, CEO and Co-Founder, Sage Bionetworks, on the development of a shared data repository of clinical data to improve disease modeling.
|
Issue 309: January 22, 2010
 Alpheus Bingham, Ph.D., Founder and Director, InnoCentive Inc., on an incentive-based open innovation model for helping organizations solve research problems.
|
Issue 305: December 18, 2009
  Per Olof Wallström, President and CEO, and Erika Söderberg Johnson, CFO, Karo Bio, on the development of innovative therapeutics targeting nuclear receptors.
|
Issue 304: December 11, 2009
 Joshua Kazam, President and CEO, Nile Therapeutics, on the company’s application of natriuretic peptides to treat heart failure.
|
Issue 303: December 4, 2009
 Kees Been, President and CEO, EnVivo Pharmaceuticals, on enhancing cognitive function in Alzheimer’s disease and schizophrenia patients.
|
Issue 302: November 20, 2009
 Benjamin Heywood, Co-Founder and President, PatientsLikeMe, on the company’s platform for connecting patients and pharma through social networking.
|
Issue 301: November 13, 2009
 Randall L. Carpenter, M.D., Co-Founder, President and CEO, Seaside Therapeutics, on the development of novel therapies for Fragile X Syndrome.
|
Issue 300: November 6, 2009
 Joseph P. Pieroni, CEO, Daiichi Sankyo Inc., on the company’s marketing strategy for Effient.
|
Issue 299: October 30, 2009
 Judy Mikovits, Ph.D, Director of Research at the Whittemore Peterson Institute, on the correlation between XMRV and Chronic Fatigue Syndrome.
|
Issue 296: October 9, 2009
 David Rose, CEO, Vitality, on GlowCaps, the company’s breakthrough technology to promote medicine adherence.
|
Issue 295: October 2, 2009
 Jennifer A. Low, MD, PhD, Global Clinical Lead for GTC-0449, Genentech, on Promising Early Clinical Results for a Hedgehog Inhibitor in Cancer.
|
Issue 293: September 18, 2009
 Julia P. Gregory, President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.
|
Issue 290: August 28, 2009
 Shingo Kajimura, Ph. D., Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.
|
Issue 289: August 21, 2009
 Robert H. Uhl, Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.
|
Issue 288: August 14, 2009
 Dr. Gail Naughton, CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.
|
Issue 286: July 31, 2009
 Neil Warma, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.
|
Issue 283: July 10, 2009:
 Vijay B. Samant, President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.
|
Issue 282: June 26, 2009
 Robert Gatenby, M.D., Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.
|
Issue 281: June 19, 2009
 Vince Kuraitis, Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.
|
Issue 280: June 12, 2009
 Gregory Perry, Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.
|
Issue 278: May 29, 2009
 Saeid Akhtari, Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.
|
Issue 277: May 22, 2009
 Shawn Lyndon, Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.
|
Issue 276: May 15, 2009
 Eric Elliott, President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.
|
Issue 275: May 8, 2009
 Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.
|
Issue 270: April 3, 2009
 Bruce S. Auerbach, M.D., FACEP, President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.
|
Issue 269: March 27, 2009:
 Yoshimi Kuroiwa, Ph.D., Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.
|
Issue 264: February 20, 2009
 Vincent Mutel, Ph.D., Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).
|
Issue 263: February 13, 2009
 Jason Hwang, M.D., Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.
|
Issue 260: January 13, 2009
 Scott Weir, PharmD, Ph.D., Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).
|
Issue 259: January 16, 2009
 Mollie Shields-Uehling, President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.
|
Issue 255: December 5, 2008
 Les Jordan, Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.
|
Issue 254: Nobember 21, 2008
 Thomas Neyarapally, Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.
|
Issue 252: Nobember 7, 2008
 Robert S. Becker, Ph.D., MBA, Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.
|
Issue 251: October 31, 2008
 James J. O’Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..
|
Issue 248: October 10, 2008
 Hironori Hozoji, Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.
|
Issue 246: September 26, 2008
 David Steinberg, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.
|
Issue 245: September 19, 2008
 Danong Chen, Ph.D., President and CEO, Theranostics Health, on protein profiling and targeted therapies.
|
Issue 244: September 12, 2008
 Javier Gonzalez-Maeso, Ph.D., Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.
|
Issue 241: August 22, 2008:
 Ellen Coleman, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.
|
Issue 240: August 8, 2008
 Nicholas J. Seay, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.
|
Issue 239: August 1, 2008
 Jacqueline A. French, MD, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.
|
Issue 233: June 13, 2008
 Howard Martin Fillit, M.D., Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.
|
Issue 231: May 30, 2008
 Jayakrishna Ambati, M.D., Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.
|
Issue 227: May 2, 2008
 Keizo Koya, Ph.D., Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.
|
Issue 225: April 18, 2008
 Anthony J. Varano, Jr., Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.
|
Issue 224: April 11, 2008:
 David G. Stevenson, S.M., Ph.D., Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.
|
Issue 223: April 4, 2008
 Joe Dougherty, Ph.D., Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.
|
Issue 221: March 20, 2008
 Adam J. Fein, Ph.D., Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.
|
Issue 217: February 22, 2008
 Bernhardt L. Trout, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.
|
Issue 215: February 8, 2008
 Akiko Yabuuchi, Ph.D., Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.
|
Issue 213: January 25, 2008
 Joshua J. Spooner, PharmD, MS, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.
|
Boro Dropulic, Ph.D., M.B.A, Founder and Chief Executive Officer, Lentigen, on the uses and advantages of his company’s Lentiviral Vector Platform.
Gerald Bernstein, M.D., F.A.C.P., Vice President for Medical Affairs, Generex Biotechnology, on Generex’s Oral-lyn insulin product and the advantages of buccal delivery.
Elizabeth Haanes, Ph.D., Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., on newly proposed Patent Office rules that would pose a hardship for the pharmaceutical industry.
Michael J. Krische, Ph.D., Professor, Department of Chemistry and Biochemistry, University of Texas at Austin, on a byproduct-free method of creating carbon-carbon bonds through hydrogenation.
William C. Crawford , Director of Industry Relations, Children’s Hospital Informatics Program, on creating a market for personally-controlled health records.
Gokhan S. Hotamisligil, M.D., Ph.D. , Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases.
Daniel J. Carlat, M.D. , Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.
Paul Burn, Ph.D. , Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF’s increased focus on translational and clinical research.
Sara Rosenbaum, Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.
Frank Burroughs , President, Abigail Alliance for Better Access to Developmental Drugs, on his organization’s push for ACCESS legislation.
Pieter Muntendam M.D. , President and CEO, and Robert N. McBurney, Ph.D., Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.
J. Scott Tarrant , VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.
Barry J. Schindler, Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.
Eileen Hilton, M.D. , President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY’s one-stop service for multi-center clinical trials.
Naomi Aronson, Ph.D. , Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.
Michael Milburn, Ph.D. , Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling.
Stuart W. Peltz, Ph.D. , President and CEO, PTC Therapeutics, on his company’s approach of using small molecules to regulate protein synthesis.
Bruce W. MacLennan, Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies.
Daniel B. Ravicher , President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.
Jacques E. Rossouw, M.D. , Chief of Women’s Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy.
Wayne Koberstein , Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.
William A. Sarraille , Partner, Sidley Austin LLP, on the potential impact of CMS’s proposed rules regarding Average Manufacturer Price (AMP) in Medicaid
Mark Kessel , Co-Founder and Managing Director, Symphony Capital, on Symphony Capital’s partnership approach to financing the development of early clinical-stage compounds.
William L. Warren , Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman’s proposed bill on follow-on biologics.
Lynn E. Eccleston , Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court’s decision on declaratory judgments in MedImmune v. Genentech.
Shin-Ichiro Imai, M.D., Ph.D. Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity.
Kenneth A. Getz, Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development.
Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic’s drug repositioning business.
Gary P. Pisano, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business.
Richard P. Burgoon, Jr., CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus’ corporate strategy.
Marc Fisher, MD, Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies.
Eric Button, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs.
Alan Goldhammer, Associate Vice President Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, on PhRMA’s views of the Institute of Medicine’s recommendations to improve drug safety.
Arthur M. Krieg, M.D., Senior Vice President, Research and Development, and Chief Scientific Officer, Coley Pharmaceutical Group, on Coley’s development of CpG oligonucleotide immunotherapeutics.
Brian P. Murphy, Partner, Morgan, Lewis & Bockius LLP, on unresolved issues in Hatch-Waxman settlement agreements.
Mihael H. Polymeropoulos, M.D., CEO, and Chip Clark, Chief Business Officer, Vanda Pharmaceuticals, on Vanda’s genomics-based approach to product differentiation in the market for CNS treatments.
Fumihiko Urano, M.D., Assistant Professor, University of Massachusetts Medical School, on the role of IRE1 in insulin biosynthesis in response to ER stress.
Bruce E. Schneider, Executive Vice President and Chief of Operations, Wyeth Research, on Wyeth’s adoption of a “learn and confirm” approach to clinical development.
Duane Thurman, Director, Prescription Drug Program, Washington State Health Care Authority, on the state’s preferred drug list and efforts to promote evidence-based, cost-effective prescribing behavior.